Ignite Creation Date:
2024-05-06 @ 1:18 PM
Last Modification Date:
2024-10-26 @ 1:12 PM
Study NCT ID:
NCT03983954
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-22
First Post:
2019-05-27
Brief Title:
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors
Sponsor:
NeoTX Therapeutics Ltd
Organization:
NeoTX Therapeutics Ltd
Conditions & Keywords Data
Conditions:
| Name |
|---|
| NSCL2 Gene Mutation |
| ER Breast Cancer |
| Ovarian Cancer |
| Cervical Squamous Cell Carcinoma |
| Pancreatic Adenocarcinoma |
| Endometrial Cancer |
| Renal Cell Carcinoma |
| Urothelial Cancer |
| Head and Neck Squamous Cell Carcinoma |
| Mesothelioma |
| Melanoma |
| Hepatocellular Carcinoma |
| Prostate Cancer |
| NSCLC |
| HER2-negative Breast Cancer |
| Triple Negative Breast Cancer |
| Bladder Cancer |
| Colorectal Cancer Metastatic |
| GastroEsophageal Cancer |
Keywords: